Treatment process of ALK and ROS1 double-rearranged lung adenocarcinoma cell carcinoma: a case report.

ABSTRACT:

Background

Anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) rearrangements are vital oncogenic drivers in non-small cell lung cancer (NSCLC), particularly in lung adenocarcinoma (LUAD), with positivity rates of 2.6% and 1.4% respectively, and are critical prognostic and predictive markers. These two rearrangements are mutually exclusive in most cases, and their co-occurrence is exceptionally rare in existing literature. Therefore, the clinical behavior, therapeutic responses, and optimal treatment strategies for this dual-rearranged subtype are poorly characterized. This case report aims to explore the efficacy of chemotherapy in this rare subtype.

Case description

A 47-year-old never-smoker woman presented with a persistent dry cough and dyspnea. Imaging and

SUBMITTER: Zou J 

PROVIDER: S-EPMC12593176 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature